debt_leverage_profile
Pre-revenue clinical-stage biotech; minimal debt, primarily equity-financed; near-zero leverage ratio typical of Series A/B stage
Inferred
Agent_Inference
interest_rate_sensitivity
Low direct sensitivity; no significant floating-rate debt, but higher rates increase cost of future equity raises and extend runway risk
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
API-grade raw materials from China (synthesis precursors) and single-source CRO/CMO partners for GLP-compliant drug manufacturing
Inferred
Agent_Inference
international_expansion_readiness
No meaningful international revenue; pre-commercial stage, so sovereign currency devaluation exposure is negligible currently
Inferred
Agent_Inference
geographic_footprint
Primarily US-based operations; no material international revenue markets; currency devaluation exposure effectively null at current stage
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
High dependency on single CMO/CRO partners for clinical supply; substitution would cause 12-18 month delays and significant cost increases
Inferred
Agent_Inference
business_model_type_primary
Clinical-stage biotech; cloud disruption would impair data/informatics operations but not core drug discovery pipeline irreparably within 30 days
Inferred
Agent_Inference
business_model_type_secondary
R&D-driven biopharma; secondary risk is loss of computational chemistry and trial data management systems requiring 60-90 day rebuild
Inferred
Agent_Inference
switching_cost_profile
Moderate API/platform coupling risk in computational tools; primary lock-in is regulatory data packages and CRO relationships, not software APIs
Inferred
Agent_Inference
howey_test_risk_index
Low Howey risk; revenue model is milestone/licensing-based pharma, not a token or investment contract structure
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Moderate HIPAA exposure from clinical trial patient data; GDPR applies if EU trial sites used; CCPA limited given no consumer-facing product
Inferred
Agent_Inference
antitrust_exposure_flag
Low antitrust risk; early-stage single-asset company with no market dominance; standard pharma IP exclusivity not typically antitrust-triggering
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
Currently 0% recurring revenue; pre-commercial, milestone and grant-based; future model targets licensing royalties and eventual product sales
Inferred
Agent_Inference
monetization_vector
Licensing/partnership deals and eventual drug sales; near-term monetization via NIH grants and pharma partnership milestones
Inferred
Agent_Inference
pricing_architecture
No commercial pricing architecture yet; future oncology drug pricing likely $100K-$300K/year course, subject to PBM and payer negotiation pressure
Inferred
Agent_Inference
pricing_power_rating
Potential high pricing power if KRAS-targeted therapy achieves best-in-class differentiation; contingent on clinical data superiority vs. AMG-510 class
Inferred
Agent_Inference
target_gross_margin_bracket
Pharma drug gross margins typically 70-85% at commercial scale; biologics/small molecules in oncology often exceed 80% gross margin
Inferred
Agent_Inference
churn_vulnerability_index
No free-rider leakage applicable; no commercial product; clinical pipeline protected by IP and regulatory exclusivity
Inferred
Agent_Inference
headcount_cost_structure
Revenue growth is highly sublinear to headcount; milestone payments and royalties scale without proportional hiring; R&D headcount is fixed-cost dominant
Inferred
Agent_Inference
marginal_cost_of_growth
Near-zero marginal cost of licensing revenue; commercial launch would require modest sales force but far below revenue-linear headcount scaling
Inferred
Agent_Inference
franchise_compliance_risk
Not applicable; no franchise network; regulatory compliance risk is FDA IND/NDA pathway, not franchise drift
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale (post-commercialization), CAC irrelevant for pharma; oncologist adoption driven by KOL influence and clinical evidence, not traditional CAC
Inferred
Agent_Inference
network_effect_present
No network effects present; drug efficacy is independent of user base; pipeline value is linear to clinical success, not adoption scale
Inferred
Agent_Inference
asset_efficiency_ratio
AI displacement risk low for core drug mechanism; computational chemistry AI could accelerate discovery but does not displace the therapeutic asset
Inferred
Agent_Inference
recession_resistance_tier
Moderate-high recession resistance; oncology drugs are non-discretionary; however, pre-commercial stage means recession impacts investor funding more than demand
Inferred
Agent_Inference
customer_segment_primary
Pharmaceutical/biotech licensing partners and acquirers as primary near-term 'customers'; oncology patient population as end-user segment
Inferred
Agent_Inference
customer_segment_secondary
NIH and government grant agencies as secondary revenue source; academic medical centers as clinical trial partners
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
Capex-light; capital deployed into CRO/CMO outsourced clinical operations and IP protection; no legacy infrastructure reallocation needed
Inferred
Agent_Inference
sec_cik
null
Inferred
Agent_Inference
ticker
null
Inferred
Agent_Inference